Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 5.849
Filtrar
1.
Zh Nevrol Psikhiatr Im S S Korsakova ; 123(11. Vyp. 2): 96-100, 2023.
Artigo em Russo | MEDLINE | ID: mdl-38127708

RESUMO

OBJECTIVE: To analyze the dynamics of depressive disorders in patients who underwent COVID-19. MATERIAL AND METHODS: The study included female patients (n=30) with mean age 35.4±3.0 years, who received inpatient treatment of depressive spectrum symptoms in accordance with ICD-10 rubrics F31-F34 and who have undergone COVID-19 (U04.9, U07.1, U07.2). Clinical-psychopathological and statistical methods were used. RESULTS: Among all patients, who underwent inpatient treatment for affective disorders, the most common symptoms were: low mood (96.7%), anxiety (83.3%), decreased interest in daily activities (40%), loss of appetite (36.7%). In patients who have had depressive symptoms before COVID-19, an increase in the number of affective spectrum symptoms (suicidal thoughts - 83.3%), as well as in asthenic manifestations in the form of increased fatigue (60%), sleep disorders (73.3%), feelings of fatigue, weakness (60%), emotional lability (40%). CONCLUSION: In patients with depressive disorders who underwent COVID-19, hypothymia is most often accompanied by anxiety, suicidal thoughts, as well as asthenic manifestations in the form of fatigue, sleep disturbances, and emotional lability. An increase in the number of asthenic spectrum symptoms in patients with depressive disorders may indicate a possible link between COVID-19 and affective pathology. The impact of coronavirus infection on the structure and dynamics of depressive disorders requires further study, taking into account the severity of affective symptoms, the impact of psychopharmacotherapy, and the severity of the infectious disease.


Assuntos
COVID-19 , Transtorno Depressivo , Humanos , Feminino , Adulto , Depressão/etiologia , Transtornos do Humor , Fadiga , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/etiologia , Transtorno Depressivo/psicologia , COVID-19/complicações
3.
J Affect Disord ; 337: 37-49, 2023 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-37230264

RESUMO

BACKGROUND: Transcutaneous auricular vagus nerve stimulation (taVNS) is used for treating depression but the efficacy and safety have not been well assessed. This study was conducted to evaluate the efficacy and safety of taVNS in depression. METHODS: The retrieval databases included English databases of PubMed, Web of Science, Embase, the Cochrane Library and PsycINFO, and Chinese databases of CNKI, Wanfang, VIP and Sino Med, and the retrieval period was from their inception to November 10, 2022. The clinical trial registers (ClinicalTrials.gov and Chinese Clinical Trial Registry) were also searched. Standardized mean difference and the risk ratio were used as the effect indicator and the effect size was represented by the 95 % confidence interval. Revised Cochrane risk-of-bias tool for randomized trials and the Grades of Recommendation, Assessment, Development and Evaluation system were used to assess the risk of bias and quality of evidence respectively. RESULTS: Totally, 12 studies of 838 participants were included. taVNS could significantly improve depression and reduce Hamilton Depression Scale scores. Low to very low evidence showed that taVNS had higher response rates than sham-taVMS and comparable response rates compared to antidepressants (ATD) and that taVNS combined with ATD had comparable efficacy to ATD with fewer side effects. LIMITATIONS: The number of studies in subgroups was small and the evidence quality was low to very low. CONCLUSIONS: taVNS is an effective and safe method for alleviating depression scores and had a comparable response rate to ATD.


Assuntos
Transtorno Depressivo , Estimulação Elétrica Nervosa Transcutânea , Estimulação do Nervo Vago , Humanos , Estimulação do Nervo Vago/efeitos adversos , Estimulação do Nervo Vago/métodos , Ensaios Clínicos Controlados Aleatórios como Assunto , Estimulação Elétrica Nervosa Transcutânea/métodos , Antidepressivos , Nervo Vago/fisiologia , Transtorno Depressivo/terapia , Transtorno Depressivo/etiologia
4.
CNS Neurol Disord Drug Targets ; 22(4): 618-621, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36043719

RESUMO

INTRODUCTION: Several COVID-19 vaccines have been implemented. However, some side effects of the vaccine have been reported, which are sometimes very harmful. Reported cases and data are still very limited regarding the psychiatric side effects of the COVID-19 vaccine. To our knowledge, only one case has been reported. In this paper, we report the case of a patient who presented an acute depressive episode 24 hours after receiving his first dose of the BNT162b2mRNA vaccine. CASE REPORT: The case was a 26-year-old man with a history of Down syndrome with moderately good autonomy for daily routine tasks. The patient, who presented hypothyroidism at 10 years old and schizophrenia at 15 years old, was doing well before the vaccination and received his first dose of the BNT162b2mRNA vaccine. Twenty-four hours later, he presented depressive symptoms that resolved spontaneously after one week. Then, fifteen days later, the symptoms reappeared, and the episode lasted for 5 weeks. The patient received 10 mg/day of escitalopram besides his usual treatment. The depressive symptoms improved considerably by the second day of treatment. DISCUSSION: The presented case illustrated significant diagnostic challenges, especially when taking into account the sequential relationship between the COVID-19 vaccine and the occurrence of depressive symptoms. A single case of depression has been reported after the administration of the COVID-19 vaccine. Scientific evidence suggests the important role of the immune system in the pathophysiology of various psychiatric disorders, including depression. CONCLUSION: Health professionals must take into consideration the potential psychiatric side effects even being rare so far, especially in vulnerable subjects. Further studies are required to establish the causal effects of depressive symptoms occurring during the weeks following the COVID-19 vaccine bolus injection.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Transtorno Depressivo , Adolescente , Adulto , Criança , Humanos , Masculino , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Transtorno Depressivo/etiologia , Vacina BNT162
5.
J Korean Med Sci ; 37(43): e309, 2022 Nov 07.
Artigo em Inglês | MEDLINE | ID: mdl-36345255

RESUMO

BACKGROUND: A considerable proportion of patients warranting total knee arthroplasty (TKA) have night pain, neuropathic pain, and/or depressive disorder, which may not be resolved by TKA. This prospective, longitudinal cohort study aimed to document the prevalence of night pain, neuropathic pain, and depressive disorder in patients with advanced knee osteoarthritis undergoing TKA and to determine whether the specific coexisting pain and/or disorder at the time of TKA adversely affected postoperative outcomes. METHODS: In this study, 148 patients undergoing TKA were longitudinally evaluated. The presence of night pain, neuropathic pain (determined using Douleur Neuropathique 4 [DN4]) and depressive disorder (determined using the Patient Health Questionnaire-9 [PHQ-9]) was determined before and 6 weeks, 3 months and 1 year after TKA. In addition, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and EuroQol-5 Dimension (EQ-5D) scores were assessed before and 1 year after TKA. Potential associations of night pain, neuropathic pain, and/or depressive disorder with pre- and postoperative WOMAC and EQ-5D scores were examined in subgroup analyses. RESULTS: Preoperatively, 72% (n = 106) of patients reported night pain, and the prevalences of neuropathic pain and depressive disorder were 15% and 17%, respectively. Preoperatively, compared with patients without night pain, those with night pain had significantly poorer preoperative WOMAC scores, but no significant difference was seen between groups 1 year after TKA. Preoperatively, the WOMAC, EQ-5D, and EQ-5D health scores of patients with neuropathic pain were not significantly different from those of patients without neuropathic pain, and there was no difference in clinical outcome scores 1 year after TKA between these groups. Preoperatively, the patients with depressive disorder showed significantly poorer preoperative WOMAC, EQ-5D, and EQ-5D health scores than those without depressive disorder, but no significant differences in scores were observed 1 year after TKA between these groups. CONCLUSION: This study revealed a considerable prevalence of night pain, neuropathic pain, and depressive disorder in patients undergoing TKA and that patients with these specific conditions reported poorer functional and quality of life scores preoperatively. However, such adverse effects disappeared after TKA. Our study findings suggest that TKA can provide satisfactory outcomes for patients with these specific conditions.


Assuntos
Artroplastia do Joelho , Transtorno Depressivo , Neuralgia , Osteoartrite do Joelho , Humanos , Artroplastia do Joelho/efeitos adversos , Estudos Prospectivos , Qualidade de Vida , Estudos Longitudinais , Resultado do Tratamento , Osteoartrite do Joelho/complicações , Osteoartrite do Joelho/cirurgia , Neuralgia/complicações , Transtorno Depressivo/etiologia
6.
Artigo em Russo | MEDLINE | ID: mdl-36168691

RESUMO

The prevalence of affective disorders in patients with Parkinson's disease (PD) is significantly higher than in the general population of people of the same age. It is known that the effectiveness of antidepressants in PD with depressive disorder is lower than in patients with primary depression. For depression resistant to standard treatments, other therapeutic strategies are available. Transcranial magnetic stimulation (TMS) is one of the most popular and safe brain stimulation methods that has been successfully used to treat primary depression. The accumulation of experience in the use of TMS has made it possible to expand the application of the method to other diseases, including PD. The article provides literature data on the use of different TMS protocols for the treatment of depressive disorder in patients with PD.


Assuntos
Transtorno Depressivo , Doença de Parkinson , Encéfalo , Transtorno Depressivo/etiologia , Transtorno Depressivo/terapia , Humanos , Doença de Parkinson/complicações , Doença de Parkinson/psicologia , Doença de Parkinson/terapia , Estimulação Magnética Transcraniana/métodos , Resultado do Tratamento
7.
Zh Nevrol Psikhiatr Im S S Korsakova ; 122(6. Vyp. 2): 22-29, 2022.
Artigo em Russo | MEDLINE | ID: mdl-35797192

RESUMO

OBJECTIVE: To identify the specific features of cognitive functioning in patients with youth chronic endogenous depressions (YCED). MATERIAL AND METHODS: Fifty-one male patients with YCED (duration 36.5±12.5 month) and 18 patients with youth depression without chronic course as a comparison group were examined. A neuropsychological battery of the following techniques was used to assess cognitive functioning: the Rey - Osterrieth complex figure test, the Design Fluency Test, the Verbal Fluency Test, the 20-question Test, the Color-Word Interference Test, arithmetic problem solving, compilation of stories based on Bidstrup's cartoons, SDMT, the Digit span. RESULTS: Based on the heterogeneity of psychopathological features of YCED, two types were identified: unitary depressions (type 1) and supplementary depressions (type 2). Among type 2 depressions, two subtypes were distinguished: with neurosis-like disorders (subtype 2.1) and with psychopathic-like disorders (subtype 2.2). The following significant differences between different types of YHED and comparison groups were revealed: on the scale «Copying¼, «Simultaneity « and points when reproducing the Rey-Osterritz figure (p=0.049, p=0.024 and p=0.043); performing the second series in the Digit Span (p=0.022); in the switching test (p=0.004) and the number of errors (p=0.046) in the Color-Word Interference Test; «expansion of the utterance program¼ when solving arithmetic problems (p=0.012). The total number of patterns in the «Visual Fluency¼ test and the execution time of the «Encryption¼ method were significantly lower in the YHED group (p=0.049 and p=0.046). CONCLUSION: Patients with YCED show signs of neurocognitive dysfunction. The patients of supplementary and unitary types of YCED demonstrate the differences in the neurocognitive profile. The revealed peculiarities show the perspective of YCED research and typification of chronic depression in adolescence due to the differences in the neurocognitive profile.


Assuntos
Transtornos Cognitivos , Disfunção Cognitiva , Transtorno Depressivo , Adolescente , Transtornos Cognitivos/diagnóstico , Depressão/diagnóstico , Depressão/etiologia , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/etiologia , Transtorno Depressivo/psicologia , Humanos , Masculino , Testes Neuropsicológicos
8.
J Nerv Ment Dis ; 210(10): 777-783, 2022 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-35687726

RESUMO

ABSTRACT: Parkinson's disease (PD) is a progressive, neurodegenerative disorder and is commonly comorbid with depression. The aim of this cross-sectional study was to assess morbidity and associated factors of depression in patients with PD. In total, 181 patients with PD were enrolled and assessed using the Mini-International Neuropsychiatric Interview. Of the sample, 51% had at least one psychiatric diagnosis. The most prevalent psychiatric disorder was depressive disorder (27.6%), followed by rapid eye movement sleep behavior disorder (9.9%), insomnia disorder (8.8%), and adjustment disorder (2.8%). Severity of anxiety, suicide risk, and anxiolytics/hypnotics use were factors associated with depressive disorder in PD patients. Furthermore, severity of anxiety was significantly linked with suicide risk. We suggest that use of a standardized structured interview for early detection of depression in PD patients is crucial. Anxiety, anxiolytics/hypnotics use, depression, and suicide risks are interrelated and warrant clinical concerns regarding PD patients.


Assuntos
Ansiolíticos , Transtorno Depressivo , Doença de Parkinson , Estudos Transversais , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/etiologia , Humanos , Hipnóticos e Sedativos , Morbidade , Doença de Parkinson/complicações , Doença de Parkinson/epidemiologia
9.
J Immunol Res ; 2022: 6724881, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35615531

RESUMO

Objective: The study is aimed at evaluating the immune-activation state before and after treatment in patients with first-episode depressive disorder (FDD) with evaluating the ILs and CRP levels and further clarifying the association between autoimmunity and the etiology and pathogenesis of FDD. Methods: We designed a case-control study. FDD patients and healthy subjects were enrolled in the FDD group and control group. Serum IL-6, IL-17, and CRP were measured before and after selective serotonin reuptake inhibitor (SSRI) therapy, as well as Hamilton rating scale for depression (HAMD) and life event scale (LES) scores. The correlations between IL-6 and IL-17 and HAMD and LES scores were analysed, and multiple linear regression analysis was performed for HAMD score. Results: 40 FDD patients and 40 healthy subjects were included in the FDD and control group from October 2009 to September 2012. Before treatment, the IL-6 (28.99 ± 5.51, P < 0.001) and IL-17 (41.15 ± 4.80, P < 0.001) in the FDD group were significantly higher than the control group (16.84 ± 3.78 and 21.68 ± 3.72, respectively). The C-reactive protein (CRP) level in two groups was comparable (P = 0.879). After treatment, the IL-6 (18.69 ± 5.07, P < 0.001) and IL-17 (30.67 ± 3.47, P < 0.001) levels and HAMD scores (6.73 ± 4.15) in the FDD group were significantly decreased than before treatment (P < 0.001, respectively). CRP level was slightly increased after treatment without statistically significant (P = 0.239). The HAMD score correlated with IL-6 (r = 0.638, P < 0.001) and IL-17 (r = 0.927, P < 0.001); the total LES and negative LES also correlated with IL-6 (r = 0.226, P < 0.05) (r = 0.366, P <0.001) and IL-17 (r = 0.348, P < 0.001) (r = 0.493, P < 0.001). Multiple linear regression analysis showed that both of the IL-6 and IL-17 had direct impact on HAMD score. Conclusion: The autoimmunity status was overactivated in FDD patients, and serum IL-6 and IL-17 levels had direct impact on the HAMD score. Patients who experienced more negative life events had higher activation level of autoimmunity status and HAMD scores, and serum IL-6 and IL-17 levels can be decreased by SSRI treatment.


Assuntos
Autoimunidade , Transtorno Depressivo , Interleucina-17 , Interleucina-6 , Estudos de Casos e Controles , Depressão/etiologia , Depressão/imunologia , Depressão/metabolismo , Transtorno Depressivo/etiologia , Transtorno Depressivo/imunologia , Transtorno Depressivo/metabolismo , Humanos , Interleucina-17/sangue , Interleucina-17/metabolismo , Interleucina-6/sangue , Interleucina-6/metabolismo
10.
Artigo em Russo | MEDLINE | ID: mdl-35394722

RESUMO

OBJECTIVE: The aim of this work was to analyze the frequency and, spectrum of mental disorders (MD), and stressful factors, as well as the characteristics of anxiety and depressive spectrum disorders (ADSD) in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). MATERIAL AND METHODS: The study included 155 patients (37 (23.9%) men and 118 (76.1%) women) aged 18 to 69 years ((M±SD) 37.7±12.3 years), including. 61 (39.3%) patients - with a reliable diagnosis of SLE according to the 2019 EULAR/ACR criteria, 48 (30.9%) patients with - SLE with secondary APS and 46 (29.7%) - with primary APS (PAPS), established according to the international criteria of 2006. RESULTS: The majority of the examined patients were found to hadve MD (current MD in 145 (93.5%) patients). ADSD prevailed in all groups: in 58 (95.1%) patients with SLE, in 42 (87.5%) - with SLE with APS and in, 39 (84.8%) - with APS. Patients with SLE were exposed to stressful events in childhood (predominantly parental deprivation) more often than patients with SLE with APS and PAPS were exposed to stressful events in childhood (93.4% versus 81.2% and 69.6%, respectively; predominantly parental deprivation). ADSD in these patients developed mainly in pre-adolescence, with a tendency towards chronic variants without remission, which leads to a greater vulnerability of the patients in this group to stressful events compared with patients with APS (p=0.05). CONCLUSION: When diagnosing and treating MD in patients with SLE and APS, special attention should be paid to the analysis of the history of stressful eventsstress history of patients, which affects the formation of common predisposing and provoking factors, both MD and RD, aggravating their course and prognosis.


Assuntos
Síndrome Antifosfolipídica , Transtorno Depressivo , Lúpus Eritematoso Sistêmico , Adolescente , Síndrome Antifosfolipídica/complicações , Síndrome Antifosfolipídica/diagnóstico , Síndrome Antifosfolipídica/epidemiologia , Ansiedade/epidemiologia , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/etiologia , Feminino , Humanos , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/epidemiologia , Masculino
11.
PLoS One ; 17(2): e0263759, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35148328

RESUMO

BACKGROUND: People with drug-resistant tuberculosis (DR-TB) are known to suffer from many mental-health disorders. This study aims to describe the proportion of patients diagnosed with psychiatric comorbidities, the different psychiatric diagnoses made, and treatment outcomes among DR-TB patients with or without psychiatric comorbidity and initiated on DR-TB treatment between January 2012 and March 2019 at Médecins Sans Frontières independent clinic in Mumbai, India. METHODS: This is a retrospective study using routinely collected clinical data. DR-TB care included individualised treatment, psychosocial support, and integrated psychiatric care. RESULTS: During the study period, 341 DR-TB patients were enrolled, with a median age of 25 years (IQR:20.0-36.5 years), 185 (54.2%) females, 143 (41.9%) with PreXDR-TB, and 140 (41.0%) with XDR-TB. All 341 patients were screened by a counsellor, 119 (34.9%) were referred for psychiatric evaluation, and 102 (29.9% of 341) were diagnosed with a psychiatric comorbidity. Among 102 diagnosed with a psychiatric comorbidity, 48 (47.0%) were diagnosed at baseline, and 86 (84.3%), or 25.2% of all 341 patients enrolled, were treated with psychotropic drugs. Depressive disorders were diagnosed in 49 (48.0%), mixed anxiety and depression in 24 (23.5%), neurocognitive disorders and anxiety in five (4.9%), and medication induced psychosis in two (2.0%). No anti-TB drugs were significantly associated with psychiatric comorbidities developed during treatment. Of 102 DR-TB patients with a psychiatric comorbidity, 75.5% (77) had successful DR-TB treatment outcomes, compared to 61.1% (146/239) not diagnosed with a psychiatric comorbidity (p = 0.014). CONCLUSION: In our setting, among people started on DR-TB treatment, and with a complex TB resistance profile, about one in three patients experienced a psychiatric comorbidity, of which half developed this comorbidity during treatment. With comprehensive psychiatric care integrated into DR-TB care delivery, treatment outcomes were at least as good among those with psychiatric comorbidities compared to those without such comorbidities.


Assuntos
Ansiedade/diagnóstico , Transtorno Depressivo/diagnóstico , Transtornos Neurocognitivos/diagnóstico , Tuberculose Resistente a Múltiplos Medicamentos/psicologia , Adulto , Antituberculosos/uso terapêutico , Ansiedade/tratamento farmacológico , Ansiedade/etiologia , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/etiologia , Feminino , Humanos , Masculino , Transtornos Neurocognitivos/tratamento farmacológico , Transtornos Neurocognitivos/etiologia , Psicotrópicos/uso terapêutico , Estudos Retrospectivos , Resultado do Tratamento , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Adulto Jovem
12.
PLoS One ; 17(2): e0263760, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35139136

RESUMO

BACKGROUND: Pregnancy is a time of major psychological changes making pregnant women more susceptible to depression and anxiety. Prevalence is higher among women living in Bangladesh, India and Pakistan, compared to high-income countries, due to poor understanding and lack of mental health integration within antenatal care. Antenatal depression/anxiety is associated with adverse outcomes including postnatal depression, low birth weight and impaired fetal development. Existing systematic reviews provided only limited information on the social determinants of antenatal depression/anxiety in these South Asian countries. OBJECTIVE: This review aimed to identify, synthesise and appraise the evidence on the social determinants associated with antenatal depression and anxiety in women living in Bangladesh, India and Pakistan. METHODS: We searched five databases (MEDLINE, Embase, PsycINFO, Scopus, Web of Science) and PROSPERO. Observational studies published between 1st January 2000 and 4th January 2021 were included if they were in the English language, used validated tools for measuring depression/anxiety in pregnant women and reported statistical associations or raw numbers. Summary estimates were obtained using random-effects model. Heterogeneity and publication bias was measured using the I2 statistic and Egger's test, respectively. This review was registered on PROSPERO (reference: CRD42020167903). RESULTS: We included 34 studies (with 27,379 women). Meta-analysis of Adjusted Odds Ratios (AOR) found that Intimate partner violence (AOR 2.48, 95% CI 1.41-4.33), unplanned pregnancy (AOR 1.53, 95% CI 1.28-1.83), male gender preference (AOR 3.06, 95% CI 1.40-6.72) and poor relationship with in-laws (AOR 2.69, 95% CI 1.25-5.80) were significantly associated with antenatal depression/anxiety. CONCLUSION: The review identified a complex range of social determinants of antenatal depression and anxiety in Bangladesh, India and Pakistan. Screening tools to identify pregnant women at high risk should be integrated within antenatal care to prevent adverse outcomes. Knowledge of these social determinants will inform the development of such screening tools and interventions.


Assuntos
Ansiedade/epidemiologia , Depressão/epidemiologia , Complicações na Gravidez/epidemiologia , Determinantes Sociais da Saúde/estatística & dados numéricos , Ansiedade/etiologia , Transtornos de Ansiedade/epidemiologia , Transtornos de Ansiedade/etiologia , Ásia/epidemiologia , Depressão/etiologia , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/etiologia , Feminino , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Violência por Parceiro Íntimo/psicologia , Violência por Parceiro Íntimo/estatística & dados numéricos , Gravidez , Complicações na Gravidez/etiologia , Cuidado Pré-Natal/estatística & dados numéricos , Prevalência
13.
Biochem Biophys Res Commun ; 593: 57-64, 2022 02 19.
Artigo em Inglês | MEDLINE | ID: mdl-35063770

RESUMO

Some of the statins have been shown to have antidepressant effects, but whether atorvastatin (AV) has antidepressant effects is unknown. This study was to investigate the effect of AV treatment on depressive behaviors. Herein, we show that AV treatment had antidepressant-like effect in physiological conditions and antidepressant effect in depressive state which depended on α7 nicotinic acetylcholine receptor (α7nAChR) expression in the ventral hippocampus (vHPC), but not α4ß2 nicotinic acetylcholine receptor (α4ß2nAchR) expression in vHPC, nor the α7nAChR and α4ß2nAchR expression in dorsal hippocampus (dHPC). By using MLA, a selective α7nAChR antagonist, we investigated the role of α7nAChR in AV treatment. Behavior tests demonstrated that MLA abolished the antidepressant effect of AV. Besides, our data showed that AV treatment increased Akt phosphorylation, brain-derived neurotrophic factor (BDNF), synaptic related protein synapsin and spinophilin expression. The phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 reversed AV-induced increase of BDNF expression, newborn neurons and antidepressant behavior effects. Our study suggests that AV plays an antidepressant role by regulating synaptic plasticity of vHPC through PI3K/Akt-BDNF signaling pathway, which may be a good choice for depression treatment.


Assuntos
Antidepressivos/farmacologia , Atorvastatina/farmacologia , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Transtorno Depressivo/prevenção & controle , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Receptor Nicotínico de Acetilcolina alfa7/metabolismo , Animais , Anticolesterolemiantes/farmacologia , Fator Neurotrófico Derivado do Encéfalo/genética , Transtorno Depressivo/etiologia , Transtorno Depressivo/metabolismo , Transtorno Depressivo/patologia , Regulação da Expressão Gênica , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Fosfatidilinositol 3-Quinases/genética , Proteínas Proto-Oncogênicas c-akt/genética , Receptor Nicotínico de Acetilcolina alfa7/genética
14.
BMC Psychiatry ; 22(1): 63, 2022 01 27.
Artigo em Inglês | MEDLINE | ID: mdl-35086502

RESUMO

BACKGROUND: Perinatal depression in women is associated with high morbidity and mortality, and has attracted increasing attention. The investigation of risk factors of perinatal depression in women may contribute to the early identification of depressed or depression-prone women in clinical practice. MATERIAL AND METHODS: A computerized systematic literature search was made in Cochrane Library, PubMed, Web of Science, and EMBASE from January 2009 to October 2021. All included articles were published in English, which evaluated factors influencing perinatal depression in women. Based on the recommendations of the Cochrane Collaboration protocols, Review Manager 5.3 was used as a statistical platform. RESULTS: Thirty-one studies with an overall sample size of 79,043 women were included in the review. Educational level (P = 0.0001, odds ratio [OR]: 1.40, 95% CI: [1.18,1.67]), economic status of families (P = 0.0001, OR: 1.69, 95%CI: [1.29,2.22]), history of mental illness (P < 0.00001, OR: 0.29, 95% CI: [0.18, 0.47]), domestic violence (P < 0.00001, OR: 0.24, 95% CI: [0.17,0.34]), perinatal smoking or drinking (P = 0.005, OR: 0.63; 95% CI [0.45, 0.87]; P = 0.008, OR: 0.43, 95% CI, [0.23 to 0.80]; respectively), and multiparity(P = 0.0003, OR: 0.74, 95% CI: [0.63, 0.87]) were correlated with perinatal depression in women. The stability of our pooled results was verified by sensitivity analysis and publication bias was not observed based on funnel plot results. CONCLUSION: Lower educational level, poor economic status of families, history of mental illness, domestic violence, perinatal smoking or drinking, and multiparity serve as risk factors of perinatal depression in women.


Assuntos
Transtorno Depressivo , Violência Doméstica , Depressão/etiologia , Transtorno Depressivo/etiologia , Feminino , Humanos , Parto , Gravidez , Fatores de Risco
15.
Eur J Orthop Surg Traumatol ; 32(6): 1105-1110, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34351512

RESUMO

INTRODUCTION: The World Health Organization (WHO) postulates that depressive disorders (DD) will be the leading cause of morbidity and mortality by 2030. Studies evaluating the association of DD following open reduction and internal fixation (ORIF) for the treatment of acetabular fractures are limited. Therefore, the purpose of this matched-control study was to determine whether DD patients undergoing ORIF for acetabular fractures have higher rates of: (1) in-hospital lengths of stay (LOS); (2) readmissions; (3) medical complications; and (4) costs of care. MATERIALS AND METHODS: A retrospective query from the 100% Medicare Standard Analytical Files (SAF) was performed to identify patients who underwent ORIF for acetabular fractures. The study group consisted of those patients with DD, whereas patients without the condition served as controls. Primary endpoints of the study were to compare in-hospital LOS, readmission rates, ninety-day medical complications, and costs of care. A p-value less than 0.01 was considered statistically significant. RESULTS: The query yielded 7084 patients within the study (ORIF = 1187, control = 5897). DD patients were found to have significantly longer in-hospital LOS (11 days vs. 10 days, p < 0.0001); however, odds (OR) of readmission rates were similar (23.16 vs. 18.68%; OR: 0.91, p = 0.26). Multivariate regression demonstrated DD to be associated with significantly higher (67.69 vs. 25.54%; OR: 2.64, p < 0.0001) 90-day medical complications. DD patients had significantly higher day of surgery ($30,505.93 vs. $28,424.85, p < 0.0001) and total global 90-day costs ($41,721.98 vs. $37,330.16, p < 0.0001) of care. CONCLUSION: After adjusting for covariates, DD is associated with longer in-hospital, complications, and costs of care in patients undergoing ORIF for the treatment of acetabular fractures, whereas readmission rates are similar. The study is vital as it can be used by orthopaedists and healthcare professionals to adequately educate these patients of the potential outcomes following their surgical procedure.


Assuntos
Transtorno Depressivo , Fraturas do Quadril , Fraturas da Coluna Vertebral , Idoso , Transtorno Depressivo/etiologia , Fixação Interna de Fraturas/métodos , Fraturas do Quadril/cirurgia , Humanos , Medicare , Redução Aberta/efeitos adversos , Redução Aberta/métodos , Estudos Retrospectivos , Fraturas da Coluna Vertebral/etiologia , Resultado do Tratamento , Estados Unidos/epidemiologia
17.
Clin Exp Dermatol ; 47(4): 709-716, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-34859487

RESUMO

BACKGROUND: During isotretinoin treatment, special attention is required to detect any symptom or change in the mental health of patients. The monitoring is complex for adolescents because of confounding factors such as mood changes associated with adolescence and puberty and the higher psychosocial impairment due to the acne itself. AIM: To determine the utility of the Adolescent Depression Rating Scale (ADRS) for monitoring symptoms in adolescents before and during isotretinoin treatment in dermatology real-life practice. METHODS: This was a national, multicentre prospective study that enrolled a random sample of dermatologists treating adolescents. An algorithm including ADRS score and its changes between consecutive visits was used. At each visit, dermatologists rated their satisfaction with ADRS and its ease of use, while patients rated the acceptability of the ADRS. RESULTS: In total, 70 dermatologists used the algorithm for 1227 visits of 283 adolescents receiving isotretinoin. Of these 70 dermatologists, 80.8% were satisfied/very satisfied with the ADRS, 82.7% considered the use of the ADRS in clinical practice to be easy/very easy and 75% considered that the ADRS enabled them to discuss more easily the risk of depression with their patients. For the patients, acceptability of the ADRS was considered good by 93.8%. CONCLUSIONS: The implementation of the ADRS could be valuable in dermatology practice, optimizing the monitoring of patients and the good use of isotretinoin.


Assuntos
Acne Vulgar , Transtorno Depressivo , Fármacos Dermatológicos , Acne Vulgar/tratamento farmacológico , Acne Vulgar/psicologia , Adolescente , Depressão/diagnóstico , Depressão/tratamento farmacológico , Depressão/etiologia , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/etiologia , Fármacos Dermatológicos/efeitos adversos , Fármacos Dermatológicos/uso terapêutico , Dermatologistas , Humanos , Isotretinoína/efeitos adversos , Isotretinoína/uso terapêutico , Projetos Piloto , Estudos Prospectivos
18.
Psicol. USP ; 33: e210159, 2022. tab, graf
Artigo em Português | LILACS, Index Psicologia - Periódicos | ID: biblio-1406393

RESUMO

Resumo Esta revisão integrativa objetivou reunir estudos sobre a depressão em pessoas sob aprisionamento no sistema carcerário. As bases de dados pesquisadas foram PePSIC, PsycINFO, SciELO e Web of Science. As ferramentas de suporte para a extração dos artigos selecionados foram o programa computacional StArt e as recomendações Prisma. Os termos usados na busca eletrônica foram "inmate", "prison", "prisoner", "penitentiary" e "depression". A amostra final foi composta por 10 estudos primários, os quais atenderam aos critérios de inclusão e à questão norteadora da revisão. Dentre os achados, a ocorrência de depressão foi evidente em todos os artigos selecionados, e o Inventário de Depressão de Beck foi o instrumento mais utilizado. Por fim, percebeu-se que a identificação precoce de sintomatologia depressiva pode minimizar prejuízos físicos e mentais na população em encarceramento.


Abstract This integrative review analyzed studies about depression among people imprisoned in the prison system. Bibliographic search was conducted on the PePSIC, PsycINFO, SciELO and Web of Science databases. Papers were selected following the PRISMA recommendations, and then extracted using the StArt software. The search strategy used the terms "inmate," "prison," "prisoner," "penitentiary" and "depression," The final sample included 10 primary studies that met the inclusion criteria and answered the research question. All selected articles indicated the occurrence of depression, assessed by the Beck Depression Inventory. Finally, early identification of depressive symptoms can minimize physical and mental harm in the incarcerated population.


Résumé Cette revue intégrative a analysé les études sur la dépression chez les personnes incarcérées dans le système pénitentiaire. Une recherche bibliographique a été menée sur les bases de données PePSIC, PsycINFO, SciELO et Web of Science. Les articles ont été sélectionnés en suivant les recommendations PRISMA, puis extraits à l'aide du logiciel StArt. La stratégie de recherche utilisait les termes "détenu", "prison", "prisonnier", "pénitencier" et "dépression". L'échantillon final comprenait 10 études primaires répondant aux critères d'inclusion et à la question de recherche. Tous les articles sélectionnés indiquaient la survenue d'une dépression, évaluée par l'inventaire de dépression de Beck. Enfin, l'identification précoce des symptômes dépressifs peut minimiser les dommages physiques et mentaux au sein de la population carcérale.


Resumen Esta revisión integradora tuvo como objetivo reunir estudios sobre la depresión en personas encarceladas en el sistema penitenciario. Las bases de datos buscadas fueron PePSIC, PsycINFO, SciELO y Web of Science. Se utilizaron el programa informático StArt como herramienta de apoyo para la extracción de los artículos seleccionados y las recomendaciones PRISMA. Los términos utilizados en la búsqueda electrónica fueron: "inmate", "prison", "prisoner", "penitentiary" y "depression". La muestra final estaba compuesta por 10 estudios primarios, que cumplían los criterios de inclusión y la pregunta guía de la revisión. Entre los hallazgos, la depresión fue evidente en todos los artículos seleccionados y el Inventario de Depresión de Beck fue el instrumento más utilizado. Finalmente, se percibió que la identificación temprana de la sintomatología depresiva puede minimizar los daños físicos y mentales en la población encarcelada.


Assuntos
Prisioneiros , Depressão/etiologia , Transtorno Depressivo/etiologia , Prisões , Revisão Sistemática
19.
BMJ Open ; 11(12): e050098, 2021 12 14.
Artigo em Inglês | MEDLINE | ID: mdl-34907048

RESUMO

INTRODUCTION: Depression is characterised by easy recurrence, high disability and high burden, and antidepressant therapy is the standard treatment. However, its treatment effect on patients with severe depressive disorder has been unsatisfactory. Previous studies have shown that repetitive transcranial magnetic stimulation (rTMS), as a neurotherapy, can effectively mitigate the severity of depressive symptoms. Yet, more evidence is still required for TMS to treat severe depression. This study will be the first systematic review of the efficacy and tolerability of TMS for treating severe depression. We expect it to guide future clinical practice of TMS for the treatment of psychiatric disorders. METHODS AND ANALYSIS: We will search for the randomised controlled trial (RCT) involving rTMS for treating depression in eight electronic databases, including PubMed, Web of Science, EMBASE, the Cochrane Library and Wanfang Database, from publication up to September 2021. We will define Improvement in depressive symptoms, the difference between pretreatment (baseline) and post-treatment as the primary outcomes. The difference between pretreatment and post-treatment changes in resting state fMRI will be regarded as the secondary outcomes. Quality assessment of the included articles will be independently performed according to the Cochrane Risk of Bias tool. ETHICS AND DISSEMINATION: Ethical approval is not essential because there is no need to collect individual patient data. And this study will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: CRD42020211460.


Assuntos
Transtorno Depressivo , Estimulação Magnética Transcraniana , Depressão/terapia , Transtorno Depressivo/etiologia , Transtorno Depressivo/terapia , Humanos , Metanálise como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto , Revisões Sistemáticas como Assunto , Estimulação Magnética Transcraniana/métodos
20.
J Oleo Sci ; 70(11): 1539-1550, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34732633

RESUMO

Unipolar depression has been recognized as one of the major diseases by the World Health Organization in the 21st century. The etiology of depression is complicated and includes genetic factors, stress, aging, and special physical status (pregnancy, metabolic syndrome, and trauma). Numerous animal and human studies have demonstrated that n-3 polyunsaturated fatty acids (n-3 PUFAs) are highly correlated to cognition and depression. These nutritional antidepressants, including EPA and DHA, have a range of neurobiological activities contributing to their potential antidepressant effects. Our preclinical and clinical studies have indicated that n-3 PUFA supplementation in addition to standard antidepressant medications may provide synergistic neuroprotective and antioxidant/inflammatory effects. To translate our preliminary findings into clinical application, this paper reviews the existing evidence on the antidepressant effects of n-3 PUFAs and the potential underlying mechanisms, which include modulation of chronic lowgrade inflammation and the corresponding changes in peripheral blood immune biomarkers.


Assuntos
Anti-Inflamatórios , Transtorno Depressivo/terapia , Suplementos Nutricionais , Óleos de Peixe/administração & dosagem , Animais , Antidepressivos/administração & dosagem , Antioxidantes , Transtorno Depressivo/etiologia , Transtorno Depressivo/imunologia , Ácidos Docosa-Hexaenoicos/administração & dosagem , Ácido Eicosapentaenoico/administração & dosagem , Ácidos Graxos Ômega-3/administração & dosagem , Óleos de Peixe/química , Óleos de Peixe/farmacologia , Humanos , Neuroprostanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...